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A novel mechanism for skeletal resistance in uremia
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total intracellular PTH was the non-PTH (1-84), most likelyA novel mechanism for skeletal resistance in uremia.
PTH 7-84.Background. In treating secondary hyperparathyroidism,
Conclusion. In patients with chronic renal failure, the pres-the target level of serum intact parathyroid hormone (I-PTH)
ence of high circulating levels of non–1-84 PTH fragmentsshould be three to five times normal to prevent adynamic bone
(most likely 7-84 PTH) detected by the “intact” assay and thedisease. In circulation, there is a non-(1-84) PTH-truncated
antagonistic effects of 7-84 PTH on the biological activity offragment, likely 7-84, which, in addition to PTH 1-84, is mea-
1-84 PTH explain the need of higher levels of “intact” PTHsured by most I-PTH immunoradiometric (IRMA) assays, giv-
to prevent adynamic bone disease.ing erroneously high I-PTH values. We have developed a new
IRMA assay in which the labeled antibody recognizes only the
first six amino acids of the PTH molecule. Thus, this new IRMA
assay (Whole PTH) measures only the biologically active 1-84
Parathyroid hormone (PTH), a single-chain polypep-PTH molecule.
tide of 84 amino acids [1], plays a critical role in theMethods. Using this new IRMA assay (Whole PTH) and
the Nichols “intact” PTH assay, we compared the ability of regulation of mineral metabolism. Ionized calcium, cal-
each assay to recognize human PTH (hPTH) 1-84 and hPTH citriol, and phosphorus are the three major regulators
7-84 and examined the percentage of non-1-84 PTH in circula- of PTH homeostasis in humans.tion and in parathyroid glands. Possible antagonistic effects of
The human PTH gene is located on the short arm ofthe 7-84 PTH fragment on the biological activity of 1-84 PTH
chromosome 11. The coding region spans more than 4in rats were also tested.
Results. In 28 uremic patients, PTH values measured with kb and consists of three exons. The first exon contains
the Nichols assay, representing a combined measurement of the 59 untranslated region of the PTH transcript. The
both hPTH 1-84 and hPTH 7-84, were 34% higher than with coding sequence spans exons 2 and 3. The spliced cyto-the Whole assay (hPTH 1-84 only); the median PTH was 523
plasmic transcript is 772 bases long. The primary transla-versus 318 pg/mL (P , 0.001). Similar results were found in
tion product, pre-pro-PTH (115 amino acids), is formed14 renal transplant patients. In osteoblast-like cells, ROS 17.2,
1-84 PTH (1028 mol/L) increased cAMP from 18.1 6 1.25 to in the rough endoplasmic reticulum of parathyroid chief
738 6 4.13 mmol/well. Conversely, the same concentration of cells [2] and is converted within seconds to pro-PTH (90
7-84 PTH had no effect. In parathyroidectomized rats fed a
amino acids) [3]. In the Golgi apparatus, pro-PTH iscalcium-deficient diet, 7-84 PTH was not only biologically inac-
converted to intact PTH (I-PTH; 84 amino acids) approx-tive, but had antagonistic effects on 1-84 PTH in bone. Plasma
calcium was increased (0.65 mg/dL) two hours after 1-84 PTH imately 15 minutes after the biosynthesis of the original
treatment, while 7-84 PTH had no effect. When 1-84 PTH and pre-pro-PTH and approximately 50 minutes prior to
7-84 PTH were given simultaneously in a 1:1 molar ratio, the PTH secretion [3, 4].
calcemic response to 1-84 PTH was decreased by 94%. In
Parathyroid hormone (1-84) is stored in secretorynormal rats, the administration of 1-84 PTH increased renal
granules awaiting one of two fates: secretion in responsefractional excretion of phosphate (11.9 to 27.7%, P , 0.001).
However, when 1-84 PTH and 7-84 PTH were given simultane- to hypocalcemic stimuli or intracellular degradation. In-
ously, the 7-84 PTH decreased the phosphaturic response by tracellular PTH degradation increases in states of hyper-
50.2% (P , 0.005). Finally, in surgically excised parathyroid calcemia when PTH secretion rates are lower. In contrast,
glands from six uremic patients, we found that 44.1% of the
the absolute rate of hormone degradation decreases in
hypocalcemic conditions when the secretion of PTH
1-84 is enhanced [5–8].Key words: adynamic bone disease, IRMA for PTH, parathyroid,
chronic renal failure, secondary hyperparathyroidism. Secondary hyperparathyroidism is a universal finding
in patients with chronic renal failure. The pathologicalReceived for publication November 11, 1999
consequences of high levels of PTH are well knownand in revised form February 7, 2000
Accepted for publication March 2, 2000 [9, 10] and have a significant impact on the life of patients
with chronic renal insufficiency. Thus, accurate monitor-Ó 2000 by the International Society of Nephrology
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ing of the levels of biologically active PTH is of great International Society of Endocrinology and the Endo-
crine Society, Minneapolis, 1996; and Colford et al, 79thimportance for the appropriate treatment of secondary
hyperparathryoidism in these patients. Annual Meeting of the Endocrine Society, Minneapolis,
1997) [25]. Thus, the purpose of this study was to charac-The development of immunoradiometric (IRMA) and
immunochemiluminometric (ICMA) two-site assays for terize a new IRMA (“Whole” PTH assay), which, in
contrast to commercially available “intact” assays, recog-human I-PTH have greatly improved the monitoring of
PTH levels in patients with chronic renal failure [11–15]. nizes only intact human PTH 1-84, and to examine the
potential of hPTH 7-84 to inhibit the biological activityThese commercial assays, also known as sandwich assays,
use two immunoaffinity-purified antibodies. One anti- of hPTH 1-84.
body, immobilized on a solid support, often a plastic
surface, serves as a “capture” antibody and binds the
METHODS
C-terminal portion of the I-PTH, as well as midregion
Characterization of the new “Whole” PTHepitopes. A second antibody, labeled with radioactive
IRMA assayiodine, in IRMA assays binds the N-terminal region of
the 1-84 PTH molecule. The development of these assays This new Whole PTH two-site assay (Scantibodies
Laboratories, Santee, CA, USA) first employs an anti-has simplified the interpretation of measurements for
PTH since theoretically they detect only PTH 1-84, or body that recognizes the 39-84 region of the PTH mole-
cule. This antibody, produced in a goat and affinity puri-I-PTH, which is biologically active. The midregion and
C-terminal–circulating fragments, which are greatly in- fied, is present in relative excess and is immobilized onto
polystyrene-coated tubes. The second antibody, also de-creased in renal insufficiency [16–21], are usually not
detected by these assays [11]. However, Quarles, Lo- veloped in a goat, was also affinity purified and recog-
nizes only the first six amino acids (1 to 6; Ser-Val-Ser-baugh, and Murphy demonstrated that in patients with
renal failure, the measurement of “intact” PTH overesti- Glu-Ile-Gln) of the human PTH molecule (Fig. 1). This
anti-hPTH (1 to 6) antibody is labeled with 125I. Themates the overall degree of secondary hyperparathyroid-
ism, since levels of “intact” PTH, which are two to three Whole PTH assay uses synthetic human PTH 1-84 as
the standard, with a limit of detection of approximatelytimes above the normal levels, correlate with normal
bone histology while normal levels of “intact” PTH in 1 to 2 pg/mL. Normal values range from 5 to 35 pg/mL.
The interassay and intra-assay coefficients of variationthese patients are associated with adynamic bone disease
[22]. Therefore, when utilizing commercial assays for were found to be between 2 and 7%, and recovery was
from 96 to 106%. The Whole PTH assay was comparedI-PTH, it is necessary to maintain the levels of PTH
above those of normal individuals to prevent adynamic with the Intact PTH assay purchased from the Nichols
Institute (I-Nichols, San Juan Capistrano, CA, USA).bone disease. This initial observation has been confirmed
by several investigators [23], and currently, it is an ac- Synthetic human PTH 1-84 and 7-84 were purchased
from Bachem (Torrance, CA, USA). To assess circulat-cepted practice to maintain serum I-PTH at levels three
to five times (200 to 300 pg/mL) above normal values to ing levels of hPTH 1-84 and non-(1-84) PTH, heparinized
blood samples were obtained before dialysis from 28prevent adynamic bone disease.
Lepage et al demonstrated that when serum from ure- patients who had been maintained on chronic hemodial-
ysis for 1.2 to 7.5 years and from 14 renal transplantmic patients is fractionated by high-performance liquid
chromatography (HPLC), two immunoreactive peaks patients (1 to 6 years).
can be detected by the Nichols two-site I-PTH assay [24].
Studies in vitroAccording to these investigators, one peak was shown
to comigrate with synthetic human PTH (hPTH) 1-84, Osteoblastic cell line. To compare the biological ef-
fects of the two peptides (hPTH 1-84 and 7-84), intracel-and a second more hydrophilic peak, eluting slightly
ahead of hPTH 7-84, accumulates in renal failure and lular cAMP production was measured in the rat osteosar-
coma cell line ROS/17.2, which has an osteoblasticaccounts for 40 to 60% of the total immunoreactivity in
these patients compared with only 10 to 20% in healthy phenotype and is known to increase cAMP production
in response to PTH. Cells were cultured in Ham’s F12individuals [25]. Clearly, a non-(1-84) PTH fragment,
“likely” containing amino acids 7-84 of the PTH mole- media containing 10% fetal bovine serum. Cells were
plated out in 12-well plates at a density of 30,000 cellscule, circulates in serum and is measured by most com-
mercial “intact” assays [24]. per well and grown to confluence. Cells were washed
three times with KHMS buffer at 378C (KCl 4.0 mmol/L,The presence of circulating inhibitors of PTH in ure-
mic patients has been proposed as one of the causes for CaCl2 1.25 mmol/L, MgSO4 1.25 mmol/L, KH2PO4 1.2
mmol/L, HEPES 10 mmol/L, NaCl 100 mmol/L, NaHCO3the need for higher levels of PTH to maintain normal
bone histology (abstracts; Colford et al, 10th Interna- 37 mmol/L, and glucose 10 mmol/L, pH 7.5). cAMP
production was measured using 500 mL of KHMS buffertional Congress of Endocrinology, San Francisco, The
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Fig. 1. Immunodetection of parathyroid hor-
mone (PTH) by the Whole PTH and Nichols
Intact PTH (I-PTH) assays. In both assays,
the immobilized antibody recognizes a large
portion of the C/midregion of the PTH mole-
cule. However, in the Whole PTH assay (top),
the labeled antibody recognizes only the first
six amino acids, while the labeled antibody
from the typical I-PTH assay (bottom) recog-
nizes a larger number of amino acids in the
N-terminal region.
(378) containing isobutyl-1-methylxantine (IBMX) 1.0 buffer containing 100 mmol/L Tris-HCl, pH 7.5, 100
mmol/L NaCl, 1 mol/L DL-dithiothreitol, and a completemmol/L and various concentrations (10211 to 1028 mol/L)
TM protease inhibitor cocktail (Boehringer-Mannheim,of hPTH 1-84 or hPTH 7-84. After a five-minute incuba-
Mannheim, Germany). Homogenates were sonicatedtion, 100 mL of 1.8 mol/L perchloric acid were added.
three times for 30 seconds each at 08C and centrifugedAfter an additional five-minute incubation at room tem-
at 10,000 3 g for 15 minutes. Supernatants were kept atperature, 100 mL of 3 mol/L KHCO3 were added to
2708C until measurements of 1-84 PTH, non-(1-84)neutralize the acid. Samples were centrifuged at 3000
PTH, and total protein were performed.rpm for 15 minutes, and the supernatants were assayed
for cAMP [26].
Studies in vivoAnalysis of PTH in human parathyroid glands. Hu-
man parathyroid glands were placed in ice-cold phos- Calcemic response. Normal female Sprague-Dawley
phate-buffered saline and processed within 30 minutes of rats weighing 225 to 250 g (Harlan, Indianapolis, IN,
parathyroidectomy. Aliquots of parathyroid tissue were USA) were parathyroidectomized (PTX) and fed a
0.02% calcium diet. Rats with a plasma calcium belowdissected, weighed, and homogenized in 500 mL of a
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7.0 mg/dL after overnight fasting were included in the
study. A 20 mg dose of hPTH 1-84 or 7-84 was given
intraperitoneally to PTX rats in four doses of 5 mg each
at 30-minute intervals (0, 30, 60, and 90 minutes). For
control studies, the rats received vehicle (saline solution)
alone. Blood was drawn via the tail at 0, 60, 90, and 120
minutes. For competition experiments, rats received an
injection of hPTH 7-84 10 minutes prior to each injection
of hPTH 1-84. The molar ratio of hPTH 7-84:hPTH
1-84 was 1:1.
Phosphaturic response. Normal female Sprague-Daw-
ley rats weighing 225 to 250 g were prepared for clearance
studies under light anesthesia. Polyethylene catheters
(PE50) were placed in the femoral artery for the collec- Fig. 2. Comparison of the recognition of hPTH 1-84 and hPTH
tion of blood and measurement of blood pressure (Blood 7-84 by the Nichols I-PTH assay. The Nichols I-PTH assay does not
differentiate between hPTH 1-84 (solid line) and hPTH 7-84 (dashedPressure Analyzer; Micro-Medic, Inc., Louisville, KY,
line).USA), in the femoral vein for infusion and in the bladder
for the collection of urine. Rats were placed in Plexiglast
holders and allowed to recover from the effect of the
anesthetic for one hour. A priming dose (0.6 mL) of
chemical inulin in saline was administered over a period
of three minutes to achieve a plasma inulin level between
50 and 100 mg/mL. A solution of saline containing inulin
to maintain this level and calcium gluconate to deliver
0.5 mg calcium was infused at the rate of 0.03 mL/min.
After equilibration, a total of four 30-minute urine col-
lections was obtained.
To assess the effects of hPTH 1-84 on phosphate excre-
tion, urine was collected during two control periods, after
which rats received a priming bolus of 1.8 mg of hPTH
1-84 followed by a sustained infusion that delivered a
total of 8.2 mg of I-PTH. After an equilibration period
of 20 minutes, two 30-minute urine collections were ob-
tained. In competition experiments, hPTH 7-84 was
Fig. 3. Comparison of the recognition of hPTH 1-84 and hPTH 7-84given five minutes prior to hPTH 1-84 at a molar ratio
by the Whole PTH assay. Unlike the Nichols I-PTH assay, the Whole
of 4:1. PTH assay does discriminate between hPTH 1-84 (solid line) and hPTH
7-84 (dashed line). Concentrations of hPTH 7-84 as high as 10,000 pgBlood samples and blood pressure measurements
were undetectable.were recorded at the beginning and end of the baseline
periods, at the beginning of the PTH infusion period,
and at the end of the study. The concentration of inulin
Statistical analysisin plasma and urine was determined by the method of
Fu¨hr, Kaczmarczyk, and Kruttgen [27]. The estimation Results are expressed as mean 6 SEM. N indicates
of the glomerular filtration rate (GFR) by inulin clear- the number of samples. The paired t-test was employed
ance and the calculation of the fractional urinary excre- to examine statistical significance, unless otherwise indi-
tion rate of phosphorus (FEPO4) were performed in the cated in the text.
standard fashion. Blood samples were centrifuged, and
plasma phosphorus and calcium concentrations were
RESULTSmeasured.
Specificity of IRMA assays for hPTH 1-84
Serum chemistries Initial studies compared the ability of the Nichols In-
Total plasma calcium levels were determined using tact (I-Nichols) PTH assay and the new Whole PTH
an atomic absorption spectrophotometer (model 1100B; assay to discriminate between the hPTH 1-84 and hPTH
Perkin Elmer, Norwalk, CT, USA). Plasma phosphorus 7-84 molecules. Figure 2 shows that the Nichols “intact”
levels were determined using an autoanalyzer (COBAS PTH assay did not discriminate between human PTH
1-84 and 7-84. However, as depicted in Figure 3, studiesMIRA Plus; Roche, Newark, NJ, USA).
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Fig. 4. Comparison of the effect of hPTH 1-84 or hPTH 7-84 on cAMP Fig. 5. Comparison of the calcemic effects of PTH isoforms. Parathy-
production in ROS 17.2 cells. Unlike hPTH 7-84, hPTH 1-84 increased roidectomized (PTX) rats fed a 0.02% calcium diet show a significant
cAMP production in a dose-dependent manner. cAMP increased from increase in plasma calcium after treatment with hPTH 1-84. In contrast,
18.1 6 1.2 to 738 6 4.1 nmol/well after treatment with 1028 mol/L hPTH hPTH 7-84 produced a slight but significant decrease in plasma calcium.
1-84. The same concentration of hPTH 7-84 had no effect. When both peptides were given together in a 1:1 molar ratio, the
calcemic response induced by hPTH 1-84 was reduced by 94% (P ,
0.001). Symbols are: (d) 1-84, N 5 9; (j) 1-84 1 7-84, N 5 6; (m)
Control, N 5 5; (r) 7-84, N 5 5.
performed using the Whole PTH assay show that hPTH
1-84 was detected with a high degree of sensitivity,
whereas hPTH 7-84 was undetectable, even at a concen-
tration as high as 10,000 pg/mL.
Studies in vitro
The results of cAMP production by ROS/17.2 cells
exposed to hPTH 1-84 or hPTH 7-84 are shown in Figure
4. Unlike hPTH 7-84, hPTH 1-84 increased cAMP pro-
duction in a dose-dependent manner. hPTH 1-84 (1028
mol/L) increased intracellular cAMP from 18.1 6 1.25
to 738 6 4.13 nmol/well. On the other hand, the same
concentration of hPTH 7-84 had no effect on cAMP
(N 5 6).
Studies in vivo in rats
Fig. 6. Comparison of the effects of hPTH 1-84 or hPTH 1-84 plus
We next examined the hPTH 7-84 fragment as a poten- hPTH 7-84 on (A) glomerular filtration rate (GFR) and (B) fractional
excretion of phosphorus (FEPO4). Control and treatment periods aretial competitive inhibitor of hPTH 1-84 in bone by mea-
denoted by open and closed bars, respectively. The phosphaturia in-suring changes in serum calcium in PTX rats. Figure 5 duced by hPTH 1-84 was decreased by 50.2% (P , 0.05) when animals
shows that the administration of hPTH 1-84 to PTX rats were treated simultaneously with 7-84 PTH, despite a significant in-
crease in GFR (P , 0.005).fed a 0.02% calcium diet increased plasma calcium by
0.65 6 0.10 mg/dL (N 5 9, P , 0.001, ANOVA). With the
administration of vehicle alone, plasma calcium changed
min), whereas fractional excretion of phosphate (FEPO4)slightly in accordance with the PTX (20.17 6 0.10
increased from 11.9 6 2.4 to 27.7 6 2.4% (N 5 10, P ,mg/dL, N 5 5). A slight but significant decrease was
0.001). When hPTH 7-84 was given simultaneously withobserved in the rats receiving hPTH 7-84 (20.30 6 0.08
hPTH 1-84, the GFR increased from 2.1 6 0.1 to 2.6 6mg/dL, N 5 5, P , 0.05). When both peptides were
0.2 mL/min (N 5 8, P , 0.05). However, despite this
given together in a 1:1 molar ratio, the calcemic response increase in GFR, the increase in FEPO4 induced by treat-induced by the administration of hPTH 1-84 alone de- ment with hPTH 1-84 was significantly decreased by
creased by 94% (N 5 6, P , 0.001, ANOVA). Thus, in 50.2% (P , 0.01) by virtue of the coadministration of
this model, hPTH 7-84 significantly inhibits hPTH 1-84 PTH 7-84.
induction of bone calcium mobilization.
Studies in humansThe phosphaturic effects of these two peptides were
then evaluated (Fig. 6). The GFR did not change in rats Figure 7 shows that the values for plasma PTH were
higher in all 28 patients on chronic dialysis when mea-infused with hPTH 1-84 (1.8 6 0.3 vs. 1.8 6 0.1 mL/
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Fig. 7. Comparison of PTH values in plasma from uremic patients
using the Nichols “intact” PTH assay (j) versus the Whole PTH assay
(d). Plasma PTH values are uniformly higher when measured with the
Nichols “intact” PTH assay than with the Whole PTH assay. The median
Fig. 9. Effects of plasma calcium on PTH degradation in dialysis pa-PTH values were 523 vs. 344 pg/mL, respectively (P , 0.001).
tients. The percentage of non-(1-84) PTH fragment (likely hPTH 7-84)
correlates positively with plasma calcium (P , 0.02) (r 5 0.638; P 5
0.0025; N 5 20).
Fig. 8. Regression analysis of plasma PTH measured by Nichols
I-PTH and Whole PTH assay in uremic patients (r 5 0.97; P , 0.001). Fig. 10. Comparison of plasma PTH levels in renal transplant patients
using Nichols I-PTH and Whole PTH assays. PTH values are higher
when measured with the Nichols I-PTH assay (P , 0.005).
sured with the I-Nichols assay compared with the Whole
assay. The median PTH values were 523 versus 344
pg/mL (P , 0.001), respectively. A regression analysis 79.8 6 24.8 pg/mL (P , 0.005) with the Whole PTH
of these data is shown in Figure 8. assay.
The association between plasma levels of non-(1-84) Finally, we examined whether intracellular cleavage
PTH, “likely” hPTH 7-84, and plasma calcium and phos- of the hPTH 1-84 molecule occurs in the parathyroid
phorus was next examined in 20 patients maintained on gland, thus producing the non-(1-84) PTH fragment. Sur-
chronic dialysis (Fig. 9). There was a positive correlation gically excised parathyroid glands from six uremic pa-
between the percentage of non-(1-84) PTH and serum tients maintained on chronic dialysis were studied. Fig-
calcium (P , 0.002), but no correlation with plasma ure 11 shows that non-(1-84) PTH fragments exist in the
phosphorus (data not shown). These studies were per- cell lysates from these parathyroid glands and represent
formed only in those patients in whom there were values 41.8 6 3.2% (P , 0.05) of the total intracellular PTH
for calcium, phosphorous, and PTH from the same blood measured by the “intact” PTH assay (that is, 1-84 PTH
sample [20]. and most likely 7-84 PTH).
In a group of 14 renal transplant patients the percent-
age of non-(1-84) PTH was found to be 44.1 6 3.1% of
DISCUSSIONthe total PTH, as measured by the I-Nichols assay and
The results of this study clearly indicate that, in addi-the Whole PTH assay (Fig. 10). The absolute PTH value
with the I-Nichols assay was 132.9 6 39.9 compared with tion to the biologically active 1-84 PTH molecule, a trun-
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cal activity of hPTH 1-84 was seen. This decrease in the
calcemic response was approximately 94%. Moreover,
similar findings were seen at the renal level. The phos-
phaturia observed in rats after the administration of the
biologically active 1-84 PTH molecule was decreased by
50.2% when both peptides were given together in a molar
ratio of 4:1 (hPTH 7-84 to hPTH 1-84). Thus, not only
at the level of the bone but at the level of the kidney,
we have demonstrated that the 7-84 PTH fragment
has antagonistic effects against the biologically active
PTH 1-84.
In addition, we have analyzed samples from 28 patients
maintained on chronic dialysis. As is shown in Figure 7,
a significantly higher value was observed when PTH was
Fig. 11. Intracellular PTH content in parathyroid glands from uremic measured by the Nichols I-PTH assay compared with
patients. The 41.8 6 3.2% of the total PTH, measured by the I-Nichols
the Whole PTH assay. The median PTH values wereassay (expressed as 100%), represents the non-(1-84) PTH fragment
523 versus 344 pg/mL, respectively (P , 0.001). More-“likely” hPTH 7-84 (h). The 1-84 PTH molecule was measured with
the Whole PTH assay (j). over, we have correlated the concentration of serum
calcium with the percentage of the non–1-84 PTH frag-
ment (likely hPTH 7-84), and found a positive correla-
tion (P , 0.002; Fig. 9). In the presence of hypercalcemia,cated non-(1-84) PTH fragment is also present in the
not only is PTH secretion suppressed but the parathyroidblood and parathyroid cells of uremic patients. Although
gland degrades a greater amount of biologically activeit has been accepted that commercial IRMA assays will
PTH, forming fragments which are biologically inactiverecognize only the 1-84 PTH biologically active peptide,
[7, 8]. In addition to the results in patients with end-
our data confirmed that the Nichols I-PTH assay also
stage renal disease, we also studied a group of 14 renal
recognizes a truncated PTH fragment (7-84), which is
transplant patients. As seen in the end-stage renal dis-
biologically inactive. On the other hand, the new assay ease patients, higher PTH values were obtained with the
(Whole PTH assay) measures only the biologically active Nichols “intact” PTH assay versus the Whole PTH assay
hPTH 1-84, since concentrations of hPTH 7-84 as high in every patient. Finally, we studied the origin of the
as 10,000 pg/mL were not recognized by this assay. non-(1-84) PTH fragment, and found that this fragment
The specificity of the Whole PTH assay along with is made in the parathyroid gland itself. Both peptides
the significant concentrations and potent inhibitory activ- were measured in lysates from the parathyroid glands
ity of PTH 7-84 may have significant clinical implications. of uremic patients using the two IRMA assay (Fig. 11).
Quarles, Lobaugh, and Murphy clearly demonstrated We found that 41.8 6 5.2% of the total PTH measured
with the Nichols “intact” PTH assay that higher concen- in these lysates represents the non-(1-84) PTH fragment.
trations of PTH, two to three times the levels found in From a clinical point of view, the results from this
normal patients, are usually associated with normal bone study offer a possible explanation for the development
histology in uremic patients [22]. On the other hand, of adynamic bone disease. When early attempts were
normal values of PTH obtained with the Nichols I-PTH made to suppress serum I-PTH to normal levels, many
assay are usually correlated with adynamic bone disease. investigators found that, although osteitis fibrosa was
Previously, other investigators also found skeletal resis- eliminated, a new condition developed in these patients.
tance to PTH [28]. Thus, it has been a common practice This condition, adynamic bone disease, is characterized
among nephrologists to maintain the levels of I-PTH in by a low number of osteoblasts and osteoclasts, a de-
the range of 200 to 300 pg/mL to prevent the develop- creased amount of osteoid tissue, an absence of marrow
ment of adynamic bone disease. fibrosis, and a mineralization defect. The development
We performed further studies with the human PTH of adynamic bone disease may not be only a histologic
7-84 fragment and found that not only is it biologically finding. New evidence is emerging that this condition
inactive as far as the production of cAMP in vitro in may produce morbidity in some patients [29]. Some pa-
ROS 17.2, but also has antagonistic effects against the tients have a propensity to develop hypercalcemia, which
biologically active 1-84 PTH when given to PTX rats. In may result from impaired calcium flux into bone [30].
these animals, we found an increase in serum calcium Our studies provide several clinically important find-
when biologically active PTH 1-84 was given alone. On ings. First, commercial I-PTH assays, specifically the
the other hand, when both peptides were given in a Nichols I-PTH assay, does not measure only true biologi-
cally active 1-84 PTH, but in addition, measures biologi-molar ratio of 1:1, a significant suppression in the biologi-
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roid hormone secretion: Proportional control by calcium: Lack ofcally inactive peptide, likely 7-84 PTH. Similar results
effect of phosphate. Endocrinology 83:1043–1051, 1968
were recently reported by other investigators [abstracts; 6. Patt HM, Luckhardt AB: Relationship of low blood calcium to
parathyroid secretion. Endocrinology 31:384–393, 1942Brossard et al, J Bone Miner Res 14(Suppl 1):444, 1999,
7. Chu LLH, MacGregor RR, Hamilton JW, Cohn DV: Studies onand Gao et al, J Bone Miner Res 14(Suppl 1):446, 1999]
the biosynthesis of rat parathyroid hormone and pro-parathryoid
[31]. Second, the biologically inactive peptide, 7-84 PTH, hormone: Adaption of the parathyroid gland to dietary restriction
of calcium. Endocrinology 93:915–924, 1973has antagonistic effects in vivo in rats at the levels of
8. Habener JF, Kemper B, Potts JT Jr: Calcium dependent intracellu-bone and kidney. Third, significant differences in plasma
lar degradation of parathyroid hormone: A possible mechanism
PTH values were seen in uremic patients and those with for the regulation of hormone stores. Endocrinology 97:431–441,
1975renal transplants when using the two assays. Fourth, the
9. Coburn JW, Slatopolsky E: Vitamin D, parathyroid hormone,origin of the non-(1-84) PTH truncated fragment is the
and the renal osteodystrophies, in The Kidney, edited by Brenner
parathyroid gland itself. Thus, the development of this B, Rector F, Philadelphia, W.B. Saunders, Co., 1991, pp 2036–2120
10. Coburn JW, Salusky I: Hyperparathyroidism in renal failure: Clin-new assay (Whole) opens a new approach to the study
ical features, diagnosis, and management, in The Parathyroid Basicof metabolic bone disease and potential treatment in and Clinical Concepts, edited by Bilizikian JP, Levine MA, Mar-
patients with renal failure. This assay measures only bio- cus R, New York, Raven Press, 1994, pp 721–745
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